Shao-Lee Lin, Acelyrin CEO (Vanja Sabic/Nasdaq, Inc)
May 5, 2023 11:34 AM EDT
Financing
Startups

Q&A: Ace­lyrin CEO Shao-Lee Lin de­tails biotech's $540M IPO, find­ing 'di­a­monds in the rough'

Kyle LaHucik

Senior Reporter

Ace­lyrin start­ed trad­ing on the Nas­daq Fri­day morn­ing in one of the largest biotech ini­tial pub­lic of­fer­ings in re­cent mem­o­ry, with $540 mil­lion in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

Ex­clu­sive Q&A: FDA's prin­ci­pal deputy com­mis­sion­er on tak­ing over for Califf, ad­comms, ac­cel­er­at­ed ap­provals and more

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

CMS looks to $2 out-of-pock­et cap for some com­mon­ly used gener­ic drugs

Zealand Phar­ma hit with sec­ond CRL for glucagon re­cep­tor ag­o­nist

GSK to pay up to $2.2B to set­tle al­most all Zan­tac-re­lat­ed court cas­es

A service from the Financial Times